Search Results
Jan 02, 2026, 14:09 ET Hong Kong Tech Exhibits Immense Potential at CES 2026 with 61 Tech Companies Ready for Global Markets
52TG0 Limited Global Pavilion
More news about: Hong Kong Tech
Dec 30, 2025, 06:16 ET OpenLedger, AI 에이전트를 위한 검증 가능한 멀티 DEX 트레이드 실행을 위해 Algebra 통합 발표
X | Korea TG
More news about: OpenLedger
Dec 12, 2025, 07:00 ET Insilico Medicine and TaiGen Achieves License Agreement to Develop and Commercialize AI-driven PHD Inhibitor for Anemia of Chronic Kidney Disease (CKD)
overseas licensing. Its flagship antibiotic, Taigexyn® (Nemonoxacin), is approved in Taiwan, China, and Russia, while the influenza antiviral TG-1000 has completed Phase III trials and filed an NDA in China.
More news about: Insilico Medicine
Dec 04, 2025, 17:31 ET Basal Cell Carcinoma Market Poised for Steady Growth Throughout Forecast Period (2025-2034) Driven by Novel Drug Approvals and Expanding Patient Pool | DelveInsight
Interferon-g, an immunostimulatory protein with anticancer properties. Stamford Pharmaceuticals holds an exclusive global license to develop SP-002 (formerly TG1042) from Transgene, a French biopharmaceutical company. A Phase IIb trial for locally advanced basal cell carcinoma (laBCC) is currently underway, with
More news about: DelveInsight Business Research, LLP
Nov 26, 2025, 08:08 ET Aurelion Inc. (NASDAQ: AURE) Has Completed its Renaming from Prestige Wealth Inc. (Previously Traded under NASDAQ: PWM)
asset management services.About Tether GoldTether Gold (XAU₮) is a digital asset offered by TG Commodities, S.A. de C.V. One full XAU₮ token represents one troy fine ounce of gold on a London Good Delivery bar. XAU₮ is available as
More news about: Aurelion Inc.
Nov 23, 2025, 11:08 ET WhiteBIT Marks 7 Years of Growth, Introduces W Group as a Global Fintech Powerhouse
https://www.youtube.com/embed/ml_WUSD-5tg (embedded video)https://youtu.be/ml_WUSD-5tgSecurity remains central to this trust. WhiteBIT ranks among
More news about: WhiteBIT
Nov 19, 2025, 09:00 ET Real Salt Lake Star Diego Luna Named Recipient of the 2025 Audi Goals Drive Progress Impact Award
https://mlssoccer.box.com/s/tg9c3fuisvinsjj0ik4l4wiqhe35ucl7 ABOUT MAJOR LEAGUE SOCCER
More news about: Major League Soccer
Nov 17, 2025, 13:50 ET Luxshare Precision logra una mejora de dos niveles en su calificación ESG de MSCI
en su cadena de suministro que trabajan con materiales 3TG. Exige que el 100% de las SOR cuenten con la certificación de conformidad del Proceso de Garantía de Minerales Responsables (RMAP) e implementa una trazabilidad completa de los minerales 3TG hasta sus países de origen.
More news about: LUXSHARE-ICT
Nov 17, 2025, 05:00 ET Ozelle Launches Next-Generation AI + Complete Blood Morphology Solution at MEDICA 2025
All-in-One, Flexible Testing: Performs multiple assays in one run, combining CBC with HbA1c, GLU/TG/TC/UA, TSH, FT3/FT4, CRP, or SAA — any combination as needed to support diverse clinical needs. From infection typing to diabetes and thyroid function
More news about: Ozelle GmbH
Nov 17, 2025, 05:00 ET Ozelle stellt auf der MEDICA 2025 seine AI + Complete Blood Morphology-Lösung der nächsten Generation vor
All-in-One, flexibles Testen: Führt mehrere Assays in einem Durchgang durch und kombiniert CBC mit HbA1c, GLU/TG/TC/UA, TSH, FT3/FT4, CRP oder SAA – jede Kombination kann je nach Bedarf zur Unterstützung vielfältiger klinischer Anforderungen zusammengestellt werden.
More news about: Ozelle GmbH
Nov 17, 2025, 05:00 ET Ozelle lance une solution de nouvelle génération IA + morphologie sanguine complète au salon MEDICA 2025
Test souple tout en un : Effectue plusieurs analyses en une seule fois, en associant la numération sanguine complète aux tests HbA1c, GLU/TG/TC/UA, TSH, FT3/FT4, CRP ou SAA, ou toute combinaison nécessaire pour répondre à divers besoins cliniques. Du typage des infections aux panels de marqueurs
More news about: Ozelle GmbH
Nov 16, 2025, 16:45 ET Luxshare Precision erreicht eine Verbesserung des MSCI ESG-Ratings um zwei Stufen auf A und demonstriert damit kontinuierliche Stärke im Bereich der nachhaltigen Entwicklung
Raffinerien (SOR) in seiner Lieferkette aus, die mit 3TG-Materialien arbeiten. Es schreibt vor, dass 100 % der SOR nach dem „Responsible Minerals Assurance Process" (RMAP) zertifiziert sein müssen, und sieht eine umfassende Rückverfolgbarkeit von 3TG-Mineralien bis zu ihren Herkunftsländern vor.
More news about: LUXSHARE-ICT
Nov 16, 2025, 05:26 ET Luxshare Precision améliore de deux crans sa note MSCI ESG pour atteindre le niveau A, preuve de sa force continue en matière de développement durable
d'approvisionnement qui utilisent des matériaux 3TG (étain, tantale, tungstène et or). Elle exige que 100 % des fonderies et raffineries soient certifiées conformes dans le cadre du processus d'assurance de minerais responsables (RMAP) et applique une traçabilité complète des minerais 3TG jusqu'à leur pays d'origine.
More news about: LUXSHARE-ICT
Nov 15, 2025, 10:10 ET Luxshare Precision Achieves a Two-Notch Upgrade to MSCI ESG Rating A, Demonstrating Continuous Strength in Sustainable Development
all smelters and refiners (SORs) in its supply chain involved in 3TG materials. It requires 100% of SORs to be certified as conformant under the Responsible Minerals Assurance Process (RMAP) and implements comprehensive traceability of 3TG minerals to their countries of origin. Chemical
More news about: LUXSHARE-ICT
Nov 15, 2025, 02:28 ET Luxshare Precision Achieves a Two-Notch Upgrade to MSCI ESG Rating A, Demonstrating Continuous Strength in Sustainable Development
all smelters and refiners (SORs) in its supply chain involved in 3TG materials. It requires 100% of SORs to be certified as conformant under the Responsible Minerals Assurance Process (RMAP) and implements comprehensive traceability of 3TG minerals to their countries of origin. Chemical
More news about: LUXSHARE-ICT
Nov 09, 2025, 23:00 ET Rona Therapeutics Presents Phase 1 Data for RN0361, a Long-Acting APOC3-Targeting siRNA, at the American Heart Association 2025 Scientific Sessions
with baseline TG >80 mg/dl showed favorable tolerability, no serious adverse events, with mild, self-limited injection-site reactions (ISRs) and transient ALT and AST elevations typical of GalNAc-conjugated siRNAs. RN0361 demonstrated dose-responsive suppression of both ApoC3 and TG through Day 180,
More news about: Rona Therapeutics
Nov 09, 2025, 23:00 ET Rona Therapeutics Presents Phase 1 Data for RN0361, a Long-Acting APOC3-Targeting siRNA, at the American Heart Association 2025 Scientific Sessions
with baseline TG >80 mg/dl showed favorable tolerability, no serious adverse events, with mild, self-limited injection-site reactions (ISRs) and transient ALT and AST elevations typical of GalNAc-conjugated siRNAs. RN0361 demonstrated dose-responsive suppression of both ApoC3 and TG through Day 180,
More news about: Rona Therapeutics
Nov 09, 2025, 03:00 ET Première thérapie mondiale d'édition génique ciblant l'APOC3 pour le traitement de l'hyperlipidémie
diagnostiqué une chylomicronémie présentait depuis longtemps des taux de triglycérides (TG) à jeun supérieurs à 12,5 mmol/L et une pancréatite aiguë récurrente. Dans l'EII d'escalade de dose du CS-121, son taux de TG à jeun a chuté de manière significative dans les trois jours qui ont suivi l'administration
More news about: CorrectSequence Therapeutics
Nov 08, 2025, 10:40 ET Clinically meaningful pivotal study results for olezarsen in sHTG presented as a late breaker at AHA Scientific Sessions
CORE and CORE2 trials assessed the impact of olezarsen SC every 4 weeks on fasting plasma TG levels and rates of acute pancreatitis in 617 and 446 patients with severe hypertriglyceridemia (sHTG, fasting plasma TG levels ≥ 500 mg/dL). The CORE and CORE2 studies met the primary endpoint
More news about: Swedish Orphan Biovitrum AB
Nov 07, 2025, 08:52 ET Weltweit erste, auf APOC3 abzielende Gen-Editing-Therapie zur Behandlung von Hyperlipidämie
diagnostiziert wurde, hatte eine lange Vorgeschichte mit Nüchtern-Triglyceridwerten (TG) von über 12,5 mmol/L und wiederkehrender akuter Pankreatitis. In der Dosiseskalationsstudie für CS-121 sank sein Nüchtern-TG-Spiegel innerhalb von drei Tagen nach einer einzigen Niedrigdosis-Verabreichung signifikant,
More news about: CorrectSequence Therapeutics
Nov 07, 2025, 08:31 ET MetaVia Presents Positive New Phase 2a Data on Vanoglipel (DA-1241) in Patients with Presumed MASH at the AASLD The Liver Meeting® 2025
hepatoprotective mechanism. Additionally, Vanoglipel 100 mg reduced pathogenic lipids in plasma lipidomic profiles, including glycerolipids (DG36:4, TG52:4) and glycerophospholipids (PE38:4, PE38:5), suggesting favorable remodeling of lipid metabolism. Vanoglipel was well tolerated
More news about: MetaVia Inc.
Nov 07, 2025, 08:24 ET La primera terapia de edición genética del mundo dirigida a APOC3 para la hiperlipidemia
diagnosticado con quilomicronemia, tenía una larga historia de niveles de triglicéridos (TG) en ayunas superiores a 12,5 mmol/L y pancreatitis aguda recurrente. En el IIT de aumento de dosis para CS-121, su nivel de TG en ayunas disminuyó significativamente dentro de los tres días posteriores a una única
More news about: CorrectSequence Therapeutics
Nov 06, 2025, 21:22 ET 世界初の APOC3 を標的とした高脂血症向け遺伝子編集治療薬
タンパク質が、トリグリセリド（TG）調節において中心的な役割を果たすことが示されています。大規模な集団解析により、APOC3 の自然な機能喪失変異を有する個体は、有害な影響を受けることなく、TG値が有意に低いことが示されています。遺伝子編集技術の進歩により、APOC3 の発現を遺伝子レベルで治療的に調節して TG 値を低下させることが可能になりました。これは、カイロミクロン血症および高トリグリセリド血症に対する潜在的な治癒アプローチを提供するものです。 CS-121 は、Correctseq によるカイロミクロン血症および高トリグリセリド血症に対する初のin
More news about: CorrectSequence Therapeutics
Nov 05, 2025, 19:42 ET The World's First Gene-Editing Therapy Targeting APOC3 for Hyperlipidemia
The patient, diagnosed with chylomicronemia, had a long history of fasting triglyceride (TG) levels exceeding 12.5 mmol/L and recurrent acute pancreatitis. In the dose-escalation IIT for CS-121, his fasting TG level dropped significantly within three days after a single low-dose administration, with
More news about: CorrectSequence Therapeutics
Nov 05, 2025, 19:00 ET The World's First Gene-Editing Therapy Targeting APOC3 for Hyperlipidemia
The patient, diagnosed with chylomicronemia, had a long history of fasting triglyceride (TG) levels exceeding 12.5 mmol/L and recurrent acute pancreatitis. In the dose-escalation IIT for CS-121, his fasting TG level dropped significantly within three days after a single low-dose administration, with
More news about: CorrectSequence Therapeutics